Daresbury Proteins are a UK-based emerging biotech, specialising in authentic mammalian proteins for high-end applications.
Focussed on quality, Daresbury Proteins offers a catalogue of histidine-tagged
recombinant human proteins for research, clinical and diagnostic applications.
Products include a range of fibroblast growth factor receptor (FGFR) proteins,
vascular adhesion protein-1 (VAP-1) and amyloid precursor proteins (APP), which
can be transferred into a client’s cGMP setting. The products, originally custom
manufactured for university-based scientists; at the time were mostly unavailable
elsewhere. As a result, the recombinants have been used in cutting-edge
functional studies in academic research, as rare antigens to generate highly
specific antibodies and to produce ground-breaking data.
Using proprietary vector technology to obtain difficult-to-express recombinant
proteins with uncompromising quality; their novel high-yield stable mammalian
expression vector system can increase protein expression by up to 50-fold
when compared to alternative mammalian-based production systems. This
superior expression system produces recombinant human proteins in human
cell lines resulting in highly active, authentic proteins without contamination by
viral genetic elements. Making the resulting highly stable proteins especially
suitable for clinical applications. The system can generate stable rapid pools 5-9
days after transfection for most proteins, without the need for additional clonal
selection and expansion, saving both time and money. The expression platform
is also able to handle larger proteins in the 50-200 kDa range.
Daresbury Proteins bring to their academic and industrial partners extensive knowledge,relating to expression of a wide range of product classes including those that are difficultto express, development of research cell lines and production of candidate targets.Daresbury Proteins can quickly generate custom stable cell lines producing a protein of interest, rivalling the timescale of a transient recombinant production approach, of weeks as opposed to months, yet offers rapid scalability for larger-scale production.